Teleflex (TFX) Stock News

Teleflex (NYSE:TFX) has announced its latest quarterly dividend. The company's Board of Directors has declared a cash dividend of $0.34 per share of common stock. The dividend will be paid on September 15, 2025, to shareholders who are on record as of August 15, 2025.

Teleflex (NYSE:TFX) reported strong Q2 2025 financial results, with GAAP revenue reaching $780.9 million, up 4.2% year-over-year, and adjusted constant currency growth of 1.0%. The company achieved GAAP diluted EPS from continuing operations of $2.77 and adjusted diluted EPS of $3.73.

Following the successful acquisition of BIOTRONIK's Vascular Intervention business, Teleflex raised its 2025 guidance, now expecting GAAP revenue growth of 9.00% to 10.00% and adjusted constant currency revenue growth of 7.70% to 8.70%. The company also increased its adjusted diluted EPS guidance to $13.90-$14.30.

By segment, Americas revenue grew 1.9%, EMEA increased 13.0%, and Asia rose 2.3% in Q2. The Interventional category showed the strongest performance with 20.4% growth, while OEM and Interventional Urology experienced declines of 11.4% and 8.1% respectively.

Teleflex (NYSE:TFX) has scheduled its second quarter 2025 earnings conference call for Thursday, July 31, 2025, at 8:00 a.m. Eastern Time. The company will discuss financial results and provide an operational update during the call.

Investors can access the call through pre-registration or via a live audio webcast on teleflex.com. An audio replay will be available from 11:00 am ET on the same day, accessible through the company website or by phone using the conference ID 69028.

Teleflex (NYSE:TFX) has completed its acquisition of BIOTRONIK's Vascular Intervention business for €760 million in cash. The acquisition significantly enhances Teleflex's global presence in the catheterization laboratory and establishes its footprint in the growing peripheral intervention market.

The acquired portfolio includes key products for coronary and peripheral interventions such as the Pantera Lux Drug-Coated Balloon Catheter, PK Papyrus Covered Coronary Stent, and Orsiro Mission Drug Eluting Stent. The deal also includes Freesolve, a CE-marked sirolimus-eluting Resorbable Metallic Scaffold technology.

Financially, the acquired products are expected to generate €177 million ($204 million) in revenues for the second half of 2025, with €91 million ($105 million) projected for Q4 2025. From 2026, the business is anticipated to deliver annual constant currency revenue growth of 6% or better. The transaction is expected to be $0.10 accretive to Teleflex's adjusted earnings per share in the first year.

Teleflex announced compelling results from a multinational study demonstrating the efficacy of their Arrow Chlorhexidine-impregnated Central Venous Catheters (CVCs). The study, involving 6,670 ICU patients across 12 units in 8 countries, showed a significant 70.5% reduction in Central Line-Associated Bloodstream Infections (CLABSI) compared to non-impregnated catheters. The Arrowg+ard Blue and Arrowg+ard Blue Plus CVCs demonstrated superior protection against various pathogens, including gram-negative bacteria, gram-positive bacteria, and fungi. Despite longer ICU stays and higher device utilization among patients with impregnated CVCs, infection rates remained significantly lower, highlighting the technology's effectiveness in high-risk scenarios.

Teleflex (NYSE: TFX) launches two major initiatives during Men's Health Month to raise awareness about prostate health issues. The company introduced the Prostate Monster ad campaign highlighting benign prostatic hyperplasia (BPH) symptoms and the Prostate Education Express mobile center for physician training and community education. The UroLift System, their leading BPH treatment, has treated over 500,000 men worldwide. The mobile education center will tour major U.S. cities, providing training on both the UroLift System and Barrigel rectal spacer. The Barrigel spacer, used before prostate cancer radiation therapy, has shown 98.5% success in reducing rectal radiation exposure by at least 25%, with average reductions of 85%. The initiatives aim to educate about BPH, which affects 14.1 million treatment-seeking men annually in the US, and promote prostate health awareness.

Teleflex (NYSE: TFX) has released its 2024 Global Impact Report, detailing the company's Corporate Social Responsibility (CSR) achievements and future objectives. The report adheres to GRI, SASB, and TCFD standards, focusing on four key pillars: Community & Sustainable Healthcare, Planet & Environment, People, and Ethics & Governance.

Key highlights include: completion of a double materiality assessment aligned with E.U. Corporate Sustainability Reporting Directive, signing the World Economic Forum Zero Health Gaps Pledge for equitable healthcare access, submission of CDP Climate Questionnaire tracking greenhouse gas emissions since 2019, and maintaining ISO 14001 certification across 6 facilities.

Teleflex (NYSE: TFX) presented new clinical data at the 2025 AUA Annual Meeting showcasing the superiority of their UroLift™ System for BPH treatment. Two key randomized controlled trials demonstrated that UroLift™ outperformed both Rezūm and tamsulosin treatments. The studies showed patients treated with UroLift™ experienced higher satisfaction rates, shorter catheterization times, and better sexual function outcomes. Notably, 70% of patients in the medication arm switched to UroLift™ treatment. Real-world data from the AQUA BPH database confirmed UroLift's superior symptom improvement at three months compared to drug treatments. Additionally, research validated the safety of Teleflex's stabilized Hyaluronic Acid (sHA) rectal spacer, showing low risk of complications in prostate cancer treatment.

A new retrospective study published in Obesity Surgery highlights significant benefits of Teleflex's (NYSE: TFX) Titan SGS™ Stapler in sleeve gastrectomy procedures. The study of 257 patients showed that at one-year post-procedure, patients treated with the Titan SGS™ Stapler experienced significantly lower rates of GERD (7.1% vs 26.4%) and de novo GERD (1.8% vs 10.9%) compared to multi-fire staplers. The Titan SGS™ Stapler, being the first and only single-fire surgical stapler specifically designed for sleeve gastrectomy, features a 23cm continuous staple line that creates consistent tubular sleeve anatomy. The study demonstrated that GERD resolution was higher in the Titan SGS™ cohort (25% vs 10.9%), while maintaining equivalent weight loss outcomes (approximately 22%) compared to traditional multi-fire staplers.